8-KLeadership Changes

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jan 3, 2017)

Filed January 3, 2017For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. filed an 8-K on January 3, 2017, reporting a change in its principal financial officer. Dr. David-Alexandre C. Gros is resigning from his positions as Senior Vice President, Chief Business Officer, and Principal Financial Officer, effective January 6, 2017, to pursue a broader operating role on the West Coast. Concurrently, the Board of Directors appointed Michael P. Mason as the new Principal Financial Officer, also effective January 6, 2017. Mr. Mason, currently Vice President of Finance and Treasurer and Principal Accounting Officer, has a long tenure with Alnylam, holding various finance roles since 2005, and possesses significant financial expertise as an MBA and CPA. His appointment indicates a move towards internal promotion to fill this critical executive position.

Key Highlights

  • 1Resignation of David-Alexandre C. Gros, MD as Senior Vice President, Chief Business Officer, and Principal Financial Officer, effective January 6, 2017.
  • 2Reason for resignation: personal interest to return to the West Coast in a broader operating role.
  • 3Appointment of Michael P. Mason as Principal Financial Officer, effective January 6, 2017.
  • 4Michael P. Mason's current roles: Vice President, Finance and Treasurer and Principal Accounting Officer.
  • 5Mr. Mason has extensive experience with Alnylam, holding various finance positions since 2005.
  • 6Mr. Mason possesses an MBA and is a certified public accountant.
  • 7Mr. Mason was granted 8,502 restricted stock units vesting on December 30, 2017.

Frequently Asked Questions

Dr. David-Alexandre C. Gros is resigning for personal reasons, as he wishes to return to the West Coast to take on a broader operating role.

Michael P. Mason has been appointed as the new Principal Financial Officer, effective January 6, 2017. He previously served as Alnylam's Principal Financial Officer from February 2011 to June 2016.

Mr. Mason has a deep history with Alnylam Pharmaceuticals, serving in various finance roles since 2005, including Corporate Controller and Senior Director of Finance. He is currently the Vice President of Finance and Treasurer and Principal Accounting Officer. He holds an MBA and is a certified public accountant (CPA).

Yes, on December 30, 2016, Mr. Mason was granted 8,502 restricted stock units under the company's 2009 Stock Incentive Plan. These units will vest in full on December 30, 2017, provided he remains an eligible participant.